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in the Treatment of Moderate to Severe
Dry Eye DiseaseSARAH LA PORTA WEBER, RODRIGO BECCO DE SOUZA, JOSE´ A´LVARO PEREIRA GOMES, AND
ANA LUISA HOFLING-LIMA PURPOSE: To evaluate the efficacy of the Esclera scleral
contact lens (SCL) treatment and its impact on clinical
testing for moderate to severe dry eye disease (DED).
 DESIGN: Prospective interventional case series.
 METHODS: A total of 41 eyes from 25 patients with
moderate to severe DED were evaluated for the Esclera
SCL treatment. Best-corrected visual acuity (BCVA),
tear osmolarity, the Schirmer I test, tear film breakup
time (TBUT), corneal and conjunctival staining, meibo-
mian grading, and Ocular Surface Disease Index and
SF-36v2 questionnaires were assessed before and after
the SCL treatment. These values were compared to assess
the real benefit of using SCL as a treatment for DED.
 RESULTS: Forty-one eyes from 25 patients were fitted
with SCL for management of DED. The underlying dis-
eases were Stevens-Johnson syndrome (22 eyes), Sjogren
syndrome (11 eyes), graft-vs-host disease (2 eyes), dry
eye after keratomileusis in situ (2 eyes), and undifferen-
tiated ocular surface disease (4 eyes). BCVA improved
from 0.703 ± 0.55 logMAR with habitual correction to
0.406 ± 0.43 logMAR with SCL (P < .001). There
was a significant decrease in tear osmolarity values
(338.1 ± 27.1 to 314.25 ± 38.8 mOsm/L, P < .001)
and van Bijsterveld scores (3.63 ± 2.33 to 2.63 ± 2.46
grade, P [ .015) between the baseline and 12 months
after SCL wear. There were also significant improve-
ments in dry eye symptoms and quality of life as assessed
by the OSDI and SF-36v2 questionnaires (both with
P< .001).
 CONCLUSIONS: The Esclera SCL treatment had a
positive impact on tear osmolarity and van Bijsterveld
score, as well as an improvement in the patients’
BCVA, dry eye symptoms, and quality of life. (Am J
Ophthalmol 2016;163:167–173.  2016 by Elsevier
Inc. All rights reserved.)
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 2016 BY ELSEVIER INC.disturbance, and tear film instability, with potential dam-
age to the ocular surface.’’1 DED is accompanied by
increased osmolarity of the tear film and inflammation of
the ocular surface and is a common disorder that occurs
more frequently in women than in men. This disorder
affects a significant percentage of the population, especially
among adults over 40 years of age. The prevalence is similar
across countries worldwide, with rates between 7% and
33%.2
Conventional treatments for DED include the applica-
tion of artificial tears, topical corticosteroids or cyclosporin
A, therapeutic soft contact lenses, and surgical procedures
such as punctal occlusion and tarsorrhaphy.3,4 However,
despite these therapies, many patients complain of
persistent symptoms and continue to show signs
associated with ocular surface changes. Additionally, the
use of scleral contact lenses (SCLs) has been recognized
as an alternative for the treatment of these patients.5–10
SCLs are large-diameter, rigid, gas-permeable devices
that are completely supported by the sclera and that vault
the cornea and limbus. SCLs maintain a fluid reservoir
in the space between the posterior surface of the lens and
the anterior surface of the cornea. The unique fitting
characteristics of SCLs enable the protection of the ocular
surface from shear forces generated by eyelid movement
over the cornea and provide continuous hydration of the
ocular surface.10,11
The purpose of this study was to evaluate the impact
of wearing the Esclera SCL on dry eye and quality of life
in patients with moderate to severe DED.METHODS
THIS PROSPECTIVE INTERVENTIONAL CASE SERIES WAS
approved by the Ethics Committee of Federal University
of Sao Paulo (Sao Paulo, Brazil). Informed consent was
obtained from all participants after the nature and possible
consequences of the study were explained, and the research
was carried out according to the tenets of the Declaration
of Helsinki.
This study evaluated 41 eyes from 25 patients who were
fitted with Esclera SCLs to treat moderate to severe DED.
When a patient had an indication for SCL in both eyes,167ALL RIGHTS RESERVED.
we analyzed the values for each eye as independent
variables, considering that each eye presents independent
anatomic and physiological features. These patients
were referred to the Contact Lens Department of Federal
University of Sao Paulo (Sao Paulo, Brazil) from February
4, 2013 to November 28, 2014. The mean age was 39.51
6 12.16 years, and 26 (63.4%) eyes of patients were female.
No patients were lost to follow-up.
This study included patients with grades 2, 3, and 4 DED
based on the DEWS report, also known as moderate to
severe DED, which presents occasionally annoying or con-
stant visual symptoms, changes in conjunctival staining
and injection, changes in corneal staining and tear signs,
changes in the meibomian glands, a tear film breakup
time (TBUT) <_10 seconds, and a Schirmer score <_10.1
The patients evaluated had symptoms that could not be
controlled by conventional treatments.
Patients with the following conditions were excluded
from the study: glaucoma, disorders that affect sensitivity
(eg, herpetic disease and diabetes mellitus), corneal decom-
pensation, active ocular infection, anatomic variations of
the eyelid and conjunctiva that impair proper SCL fitting,
pregnancy, and an inability to correctly handle and care for
the SCLs.
For SCL fitting, a trial set with the following parameters
was used: scleral design (Esclera; Mediphacos Inc,
Belo Horizonte, Brazil); nonfenestrated; diameter,
16-18.2 mm; available sagittal vaults, 4.12-6.27 mm;
DK/T, 141 (ISO/Fatt); available powers from 20 to þ20
diopters.
All SCL fittings were performed by a practitioner expe-
rienced in the field (S.L.P.W.). The 3 parameters that char-
acterize the Esclera SCL are the sagittal depth, base curve,
and lens diameter. The initial diagnostic lens was selected
based on suggestions in the manufacturer’s fitting guide12
according to the patient’s corneal topographic diagnosis,
such as moderate cone, advanced cone, pellucid marginal
degeneration, or post-penetrating keratoplasty.
The ideal Esclera SCL for fitting had a size at least 2 mm
greater than each side of the limbus and a minimum apical
clearance of 100 mm. The SCL should not touch the
cornea, and the edges of the SCL should not exhibit
vascular impingement, conjunctival blanching, or scleral
indentation. Those patients with ideal fits were allowed
to wear the lenses for 1 hour; then, the apical clearance
was reassessed, and spherocylindrical over-refraction was
performed.
Follow-up visits occurred at months 0, 1, 3, 6, and 12.
Subjective and objective assessments of DED were
conducted before the fitting and 6 and 12 months after
SCL use. All dry eye tests were performed by the same
observer (S.L.P.W.), and the minimum follow-up period
was 12 months.
The clinical examinations included assessment of
the best-corrected visual acuity (BCVA) using Early
Treatment Diabetic Retinopathy Study (ETDRS) charts168 AMERICAN JOURNAL OF(CC-100; Topcon Corp, Tokyo, Japan), and this value
was recorded as the Snellen equivalent. The corresponding
logMAR was then derived from the Snellen equivalent.
At each visit, in order of performance, tear osmolarity,
slit-lamp examination, the Schirmer I test, the TBUT,
corneal and conjunctival staining, and meibomian grading
were assessed for the eyes evaluated. All patients were
instructed to discontinue use of the SCLs 1 day prior to
dry eye testing.
Osmolarity was measured using a lab-on-a-chip system to
simultaneously collect and analyze the electrical imped-
ance of a 50-nL tear sample from the inferior lateral
meniscus (TearLab Osmolarity System; OcuSense, San
Diego, California, USA).13,14 We excluded patients with
Schirmer I test scores equal to zero from this analysis.
A slit-lamp examination at a magnification of 10-163
was used to detect the presence of active inflammation or
structural changes, as evidenced by scarring in the eyelid
and conjunctiva, neovascularization, opacities, or thinning
of the cornea. The tear meniscus height was classified as
present, reduced, or absent.
Tear fluid production was examined with a 5-minute
Schirmer I test using a standardized filter strip (Ophthal-
mos Inc, Sao Paulo, Brazil) without anesthetic. The
TBUT was measured by calculating the average of 3
consecutive tear breakup times, which were determined
manually using a stopwatch.
Corneal staining was evaluated after fluorescein instilla-
tion according to the van Bijsterveld score (VBS)15 (grades
of 0-3 for 3 regions of the ocular surface). Conjunctival and
corneal staining with sodium lissamine green dye was
assessed using the Oxford score,16 for which grades of 0-5
are assigned to 3 regions of the ocular surface for a possible
total of 15 points.
For meibomian gland evaluation, digital pressure was
applied to the upper tarsus, and meibum expression was
evaluated semiquantitatively according to the following
grades: 0, clear meibum easily expressed; 1, cloudy meibum
expressed with mild pressure; 2, cloudy meibum expressed
with more than moderate pressure; 3, meibum not
expressed even with strong pressure.17
Symptoms were assessed at baseline and after 12 months
of SCL use using a validated Portuguese version of the
Ocular Surface Disease Index (OSDI) (Allergan Inc,
Irvine, California, USA). The OSDI scores range from
0 to 100, with higher scores representing greater
disability.18 In addition, the SF-36v2 questionnaire (Qual-
ityMetric Inc, Lincoln, Rhode Island, USA)19 was used to
assess patient quality of life (QoL) before and after SCL use.
For each domain, a score ranging from 0 (worst health) to
100 (best health) was calculated.
 STATISTICAL ANALYSIS: Statistical analyses were
performed with the statistical software package SPSS for
Windows (version 14.0; SPSS, Inc, Chicago, Illinois,
USA). To compare the results obtained at baseline andMARCH 2016OPHTHALMOLOGY
TABLE 2. Topical Dry Eye Disease Therapy and Ocular
Surgeries Attempted Before the Esclera Scleral Contact
Lens Evaluation
Prior topical therapy, n/% (n ¼ 41 eyes)
Artificial tears preservative-free 39/95.1
Artificial tears with preservative 7/17.1at 6 and 12 months after SCL use, we performed the
Cochran test, the Friedman test, analysis of variance, and
paired t tests, depending on the variable analyzed.
Normality assumption was evaluated by the Shapiro-Wilk
test. In addition, when necessary, Tukey multiple compar-
isons were performed. Differences were considered statisti-
cally significant when the P value was less than .05.Gels/ointments 11/26.8
Topical antibiotic eye drops 10/24.4
Corticosteroid eye drops 24/58.5
Cyclosporine A 0.05% eye drops 4/9.75
Autologous serum tears 1/2.4
Prior ocular surgery, n/%
Punctal occlusion 14/34.1
Tarsorrhaphy 7/17.1
Penetrating keratoplasty 3/7.3
Eyelid reconstruction 10/24.4
Electrolysis of cilia 11/26.8
Salivary gland autotransplantation 7/17.1
Coating with amniotic membrane 2/4.9RESULTS
THIS STUDY EVALUATED 41 EYES FROM 25 PATIENTS WHO
were fitted with SCLs to treat DED. Demographic informa-
tion on all subjects is summarized in Table 1. The topical
dry eye therapy and ocular surgeries attempted before the
SCL evaluation are described in Table 2. We noted that
most of the patients had previously undergone certain
treatment for DED, as suggested by DEWS.1 Another group
of potential subjects (15-20 eyes) attempted to enroll in the
study but could not participate because they were unable to
handle the contact lens.TABLE 1. Demographic Data of Dry Eye Disease Patients
Evaluated for Esclera Scleral Contact Lens Therapy
Demographic Value
Eyes/patients (n) 41/25
Laterality of fit (n)
Right 4
Left 5
Both 16
Age at SCL fitting (y)
Mean 6 SD 39.51 6 12.158
Range 44
Female/male sex (%) 26 eyes (63.4)/
15 eyes (36.6)
UDVA (logMAR)
Mean 6 SD 1.047 6 0.538
Range 1.90
BCVA with habitual correction (logMAR)
Mean 6 SD 0.703 6 0.555
Range 2.00
Previous spectacle wear (n/%)
Yes 16/39
No 25/61
Previous contact lens wear (n/%)
Yes 21/51.2
No 20/48.8
Dry eye gradinga (%)
Grade 1 0
Grade 2 37.5
Grade 3 21.9
Grade 4 40.6
BCVA ¼ best-corrected visual acuity; SCL ¼ scleral contact
lens; UCVA ¼ uncorrected distance visual acuity.
aAccording to DEWS.1
VOL. 163 THE USE OF THE ESCLERA SCLERAL COThe underlying diseases were Stevens-Johnson
syndrome (22 eyes), Sjogren syndrome (11 eyes), graft-
vs-host disease (GVHD) (2 eyes), dry eye after in situ
keratomileusis (LASIK) (2 eyes), and undifferentiated
ocular surface disease (4 eyes).
The BCVA improved from 0.703 6 0.55 logMAR
(mean 6 SD; Snellen equivalent, 20/100) with habitual
correction to 0.406 6 0.43 logMAR (Snellen equivalent,
20/50) with the SCL (P < .001). All patients who were
fitted with SCLs had an improved BCVA, defined as a
gain of 2 or more Snellen lines. The mean SCL wear
time per day was 11.6 6 3.0 hours (range, 5-15 hours).
The slit-lamp findings present at baseline were corneal
neovascularization (77.8%), corneal opacity (61.1%),
corneal thinning (30.6%), and corneal keratinization
(16.7%). Eyelid scarring was present in 41.7% of the eyes
studied. None of the slit-lamp findings showed changes
between the baseline and the 12-month evaluations
(P ¼ 1.000). The status of the meibomian glands was
2.8% grade 0þ, 50% grade 1þ, 44.4% grade 2þ, and
2.8% grade 3þ (Table 3). The analysis of the tear meniscus
height showed that 15 eyes (36.6%) had no meniscus,
22 (53.6%) had a reduced meniscus, and 4 (9.8%) had a
present meniscus at baseline. These results showed no
changes between the baseline data and those data obtained
after 6 and 12 months (P ¼ 1.000).
The parameters of the final Esclera SCL fitting were a
mean lens sagittal depth of 4.74 6 0.38 mm and a mean
lens base curve of 7.28 6 0.57 mm. The diameter of the
fitted SCL ranged from 16.0 to 17.5 mm, with an average
of 16.43 mm.
Table 3 shows the outcomes of the DED testing at base-
line and then 6 months and 12 months after SCL wear.
We noticed that tear osmolarity and the VBS were signif-
icantly different between the analyzed periods (P < .001169NTACT LENS FOR DRY EYE DISEASE
TABLE 3. Dry Eye Disease Testing Outcomes at Baseline and 6 and 12 Months After Esclera Scleral Contact Lens Wear
Baseline (n ¼ 41) 6 Months (n ¼ 41) 12 Months (n ¼ 41) P Value
Tear osmolarity (mOsm/L) 338.1 6 27.1 313.1 6 44.1 314.25 6 38.8 <.001a
Schirmer I test (mm/5 min) 3.2 6 3.443 2.85 6 3.407 2.5 6 3.204 .372
TBUT value (s) 2.65 6 1.785 2.9 6 1.586 2.9 6 1.518 .555
van Bjisterveld score (grade) 3.63 6 2.337 3.04 6 2.458 2.63 6 2.464 .015a
Oxford score (grade) 5.33 6 3.975 4.5 6 2.485 4.42 6 2.376 .209
Meibomian gland status (grade) 2.00 6 0 2.00 6 0 2.00 6 0 1.000
TBUT ¼ tear film breakup time.
Abnormal values: Tear osmolarity >_316 mOsm/L; Schirmer I test <_5 mm/5 min; TBUT <10 seconds.
Values expressed as mean 6 standard deviation.
aStatistically significant correlation (P < .05); analysis by repeated-measures analysis of variance test.
TABLE 4. Questionnaire Evaluation of Dry Eye Disease
Patients Before and 12 Months After Esclera Scleral Contact
Lens Wear
Questionnaire Baseline (n ¼ 25)
After 12 Months
(n ¼ 25) P Valuea
OSDI 30.71 6 14.13 11.29 6 11.24 <.001
SF-36v2b
Physical functioning 91.25 6 3.24 97.47 6 5.22 <.001
Social functioning 73.38 6 21.32 84.55 6 18.96 <.001
Physical problems 54.37 6 34.14 61.46 6 40.33 <.001
Bodily pain 66.48 6 21.94 72.28 6 23.46 <.001and P ¼ .015, respectively). Eight eyes were excluded from
the tear osmolarity analysis because they presented
Schirmer I test scores equal to zero for at least 1 of the
measurements.
The tear osmolarity exhibited a statistically significant
decrease between different time points: baseline >
6 months (P < .001), baseline > 12 months (P < .001),
and 6 months¼ 12 months (P¼ .929), as determined using
the Tukey test at a 1% level of probability. The statistical
significance of the differences in the VBS between different
time points were as follows: baseline ¼ 6 months (P ¼
.194), baseline > 12 months (P ¼ .011), and 6 months ¼
12 months (P ¼ .426), as determined using the Tukey
test at a 1% level of probability.
The other DED tests shown in Table 3, such as the
Schirmer I test, TBUT assessment, the Oxford score, and
assessment of the meibomian gland status, showed no sig-
nificant difference between baseline and after 6 and
12 months of SCL wear.
Ocular surface symptoms assessed by OSDI score were
significantly better after 12 months of SCL wear
(P < .001) (Table 4). The patient QoL assessed by
SF-36v2 questionnaire was also significantly better
after 12 months of SCL wear in the 8 domains evaluated
(P < .001) as described in Table 4.
The mean follow-up period was 16.3 months (range,
12.2-24.5 months). During the follow-up, 1 eye (2.44%)
presented with a corneal abrasion during lens insertion,
and no patients discontinued SCL wear.Emotional problems 55.55 6 41.14 68.75 6 43.87 <.001
Mental health 65.55 6 12.90 74.12 6 19.02 <.001
Energy and vitality 59.08 6 10.80 68.76 6 12.40 <.001
General perception
of health
48.55 6 15.89 62.09 6 18.33 <.001
OSDI ¼ Ocular Surface Disease Index.
Values expressed as mean 6 standard deviation.
aPaired t test.
b1998 US general population norms and norm-based
scoring.17DISCUSSION
THE 2 MAIN MECHANISMS OF DED ARE DRIVEN BY TEAR
hyperosmolarity and tear film instability. Tear hyperosmo-
larity arises as a result of water evaporation from the
exposed ocular surface, low aqueous tear flow, or excessive
evaporation or owing to a combination of these events.
Tear film instability also suggests higher exposure of the170 AMERICAN JOURNAL OFocular surface, resulting in damage to the epithelial surface
and the glycocalyx and goblet cell mucin disorders.1 This
process is accompanied by ocular surface inflammation,
which causes dysfunction of the lacrimal glands, changing
the composition to a state of tear hyperosmolarity, and
then completes the vicious circle of tissue damage.20
The degree of tear film hyperosmolarity has been proven
to be the most effective single measure for diagnosing
DED,21–23 and moderate to severe dry eye is characterized
by tear osmolarity higher than 316 mOsm/L.13,23,24
Over the past decade, several studies have investigated
different SCLs for the treatment of DED.5–8,10,25–33 This
interest is due to the introduction of new SCL designs
and the improvement of SCL materials and oxygen
permeability. The use of SCLs is usually indicated
for treating DED in cases of conventional treatmentMARCH 2016OPHTHALMOLOGY
failure.10,29 The SCL acts as a protective covering for the
cornea and conjunctivae by controlling evaporation and
maintaining direct contact between the fluid and the
corneal epithelium. The SCL also protects the cornea
from abrasions and mechanical trauma, which commonly
result from eyelid scar irregularities and misdirected
eyelashes.
The present study evaluated the impact of the Esclera
SCL on dry eye and quality of life in patients with moderate
to severe DED. Of the 41 eyes assessed in this study, 62.5%
were classified as grade 3 or 4 according to DEWS.1 This
percentage explains the severity of the slit-lamp findings
and the DED testing outcomes (Table 3) observed during
the study. Another group of potential subjects (15-20
eyes) attempted to enroll in the study but could not partic-
ipate because they were unable to handle the contact lens.
The main difficulty was lens placement in the eye by the
patients. Given that the SCL is a large-diameter lens and
that it should be completely filled with liquid, its placement
requires manual skill. Other factors, such as low vision, a
lack of previous experience with contact lenses, hand
tremors, anatomic abnormalities of the fingers (eg, osteoar-
thritis), or insecurity due to living alone were decisive for
the exclusion of these patients from our study.
Most of the patients evaluated had Stevens-Johnson syn-
drome (53.7%) or Sjogren syndrome (26.8%). Our study
institution is one of the national reference centers for treat-
ing these diseases.
We noticed a significant improvement in the BCVA
(gain of 2 or more Snellen lines) in all patients who
were fitted with SCLs, as also described in previous
studies.5,10,11,29–33 In addition to correcting the refraction
of the patient, the SCL promotes the replacement of an
irregular ocular surface, with findings such as opacities,
scarring, and corneal neovascularization, with a more
regular surface. The improvement in the quality of the
BCVA could also have been the result of reducing the
dry eye symptoms, including irritation, photophobia, and
foreign-body sensation, described in the OSDI question-
naire (Table 4), which increases comfort when the eyes
are open.
In our study, the diameter of the fitted SCL ranged from
16.0 to 17.5 mm, with an average of 16.43 mm. Previous
studies have investigated even larger lenses, with diameters
ranging from 15.0 to 23.0 mm.5,9–11,26–32 We believe that
the diameter of the lens used in the present study
facilitated successful SCL fittings in patients with eyelid
scarring (41.7%).
We observed a statistically significant decrease in the
mean tear osmolarity between baseline and after 6 months,
and this decrease was maintained after 12 months of SCL
wear. The reduction in tissue damage, as assessed based
on van Bijsterveld corneal staining, showed a downward
trend; this trend was not significant after six months of
SCL wear but became significant after 12 months. This
finding may suggest that the process of tecidual damageVOL. 163 THE USE OF THE ESCLERA SCLERAL COwas still active during and after normalization of the tear
osmolarity. The SCL reduces tear evaporation, which
allows several of the tear properties to be gradually reestab-
lished, regardless of the etiology of the dry eye.
However, several of the measurement parameters related
to tear film instability, such as the Schirmer I test results
and the TBUT, exhibited no statistically significant
changes between periods evaluated, as shown in Table 3.
Therefore, the use of the SCL allowed only a partial
increase in ocular surface epithelialization because it
reverted just 1 of the 2 core mechanisms of damage—
namely, the hyperosmolarity—and did not alter the tear
film instability.
According to the OSDI, most patients experienced
many symptoms associated with dry eye, such as foreign-
body sensation, ocular fatigue, and eye redness. However,
compared with the value before SCL use, the OSDI showed
consistent improvement after SCL use. The average OSDI
value ranged from 30.71 to 11.29 after 12 months of SCL
use (P < .001), with a higher value indicating more severe
ocular complaints related to dry eye. Previous studies have
shown a significant improvement between pre-SCL and
post-SCL OSDI scores, which indicates that the patients
experienced improvements in ocular surface comfort and
visual function.21 These results may explain why despite
the disadvantages of the lens, such as difficulties in
handling and care, patients maintained their use during
the follow-up period. In addition, we observed amean dura-
tion of SCL wear per day of 11.6 6 3.0 hours (range, 5-15
hours), which also demonstrates the adherence to DED
treatment with the SCL.
The patient QoL assessed by SF-36v2 questionnaire was
also significantly better after 12months of SCLwear in each
of the 8 domains evaluated (P < .001). The SF-36 was
chosen because it is one of the most widely used measures
in health services research and has already been translated
into the Portuguese language and validated.19,34,35 Dry eye
disease is clearly associated with poorer QoL, with
particular impact on the physical component summary.36
In our study, the symptoms of moderate to severe dry eye
and its primary diseases affected the QoL in general, espe-
cially involving the physical problems, bodily pain,
emotional problems, mental health, energy and vitality,
and the general perception of health (Table 4). This
demonstrates that moderate to severe DED has huge impact
on the patients’ quality of life.
Our study had certain limitations, such as the small
sample of eyes evaluated and the lack of a control group.
In addition, we analyzed the values for each eye as indepen-
dent variables, which could lead to some bias. However,
despite these limitations, we could demonstrate that
Esclera SCL treatment had a positive impact on tear osmo-
larity and the VBS and also improved BCVA and patients’
quality of life. Regardless, more studies with a larger sample
size and longer-term follow-up are needed in this field to
investigate the impact of SCLs.171NTACT LENS FOR DRY EYE DISEASE
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